These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19105960)

  • 41. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
    Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
    Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients.
    Liu CJ; Chen PJ; Lai MY; Kao JH; Jeng YM; Chen DS
    Hepatology; 2003 Mar; 37(3):568-76. PubMed ID: 12601355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C.
    Loulergue P; Mir O; Sogni P
    AIDS; 2012 Mar; 26(5):655-6. PubMed ID: 22398573
    [No Abstract]   [Full Text] [Related]  

  • 45. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
    Hoefs JC; Morgan TR
    Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713
    [No Abstract]   [Full Text] [Related]  

  • 46. [HIV and hepatitis C coinfection].
    Stoehr A; Brinkmann K; Sabranski M
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():54-5, 57. PubMed ID: 19024919
    [No Abstract]   [Full Text] [Related]  

  • 47. Acute hepatitis C and HIV coinfection.
    Dionne-Odom J; Osborn MK; Radziewicz H; Grakoui A; Workowski K
    Lancet Infect Dis; 2009 Dec; 9(12):775-83. PubMed ID: 19926037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of HBV/HCV coinfection.
    Potthoff A; Manns MP; Wedemeyer H
    Expert Opin Pharmacother; 2010 Apr; 11(6):919-28. PubMed ID: 20166841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis drug gets approval for coinfection treatment.
    AIDS Patient Care STDS; 2005 May; 19(5):351. PubMed ID: 15916498
    [No Abstract]   [Full Text] [Related]  

  • 50. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 51. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha-2a and ribavirin.
    Sperati CJ
    Clin Nephrol; 2013 Sep; 80(3):231-4. PubMed ID: 22541681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV and hepatitis C virus coinfection: bad bedfellows.
    Schooley RT
    Top HIV Med; 2005; 13(4):112-6. PubMed ID: 16304454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.
    Moreno C; Deltenre P; Pawlotsky JM; Henrion J; Adler M; Mathurin P
    J Hepatol; 2010 Jan; 52(1):25-31. PubMed ID: 19931204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches.
    Yeung E; Chung RT
    J Hepatol; 2005 Nov; 43(5):748-50. PubMed ID: 16171895
    [No Abstract]   [Full Text] [Related]  

  • 57. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
    Halfon P; Cacoub P
    Rev Med Interne; 2011 May; 32(5):271-4. PubMed ID: 21126807
    [No Abstract]   [Full Text] [Related]  

  • 58. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current treatment of hepatitis C virus infection].
    Lörke J; Avci A; Erhardt A; Heintges T; Häussinger D
    Dtsch Med Wochenschr; 2005 Jul; 130(30):1773-7. PubMed ID: 16049884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
    Torriani FJ; Ribeiro RM; Gilbert TL; Schrenk UM; Clauson M; Pacheco DM; Perelson AS
    J Infect Dis; 2003 Nov; 188(10):1498-507. PubMed ID: 14624375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.